Neurocrine biosciences supports tardive dyskinesia awareness week by advocating for routine screening and monitoring

Approximately 600,000 people in the united states live with tardive dyskinesia (td), and about 65% have not yet been diagnosed1-3 the diagnosis rate can be improved by increasing routine td screenings in people treated with antipsychotic medication4   san diego , may 6, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today renewed its commitment to increasing awareness and advancing care for people living with td during tardive dyskinesia awareness week, may 5-11. td is a persistent, involuntary movement disorder associated with the use of antipsychotic medication that may be necessary to treat individuals living with mental illness, such as bipolar disorder, major depressive disorder, schizophrenia and schizoaffective disorder.1,5-7 for seven consecutive years, td awareness week – which occurs each year during mental health awareness month – has brought together the mental health advocacy community and states across the country to recognize the approximately 600,000 people in the u.s. living with td.1,2 this year, neurocrine is joining participants of td awareness week to conduct initiatives nationwide to decrease stigma, improve recognition and increase routine screenings, diagnosis and awareness of appropriate treatment of td.
NBIX Ratings Summary
NBIX Quant Ranking